Abatacept (powder)

Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases[1][2][3].

Product Specifications

CAS Number

[332348-12-6]

Product Name Alternative

CTLA4lg (powder) ; BMS-188667 (powder) ; Orencia

UNSPSC

12352203

Target

CTLA-4

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/abatacept-powder.html

Purity

99.00

Solubility

10 mM in DMSO

Smiles

[Abatacept(powder)]

Molecular Weight

(84.4 kDa)

References & Citations

[1]Kiykim A, et al. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. J Allergy Clin Immunol Pract. 2019 Jun 22.|[2]Lon HK, et al. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. J Pharmacokinet Pharmacodyn. 2013 Dec;40 (6) :701-12.|[3]Patakas A, et al. Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells. Arthritis Rheumatol. 2016 Mar;68 (3) :627-38.